Proteomic signatures of canine myxomatous mitral valve disease reveal candidate biomarkers associated with progression from stage B2 to stage C
This study utilizes plasma proteomics to identify specific protein signatures and candidate biomarkers that distinguish between ACVIM stages B2 and C of canine myxomatous mitral valve disease, offering molecular insights into disease progression and potential targets for therapeutic monitoring.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Dogs, like people, can develop a common heart condition where the valve between two chambers of the heart becomes weak and leaky. This disease, known as myxomatous mitral valve disease, causes blood to flow backward, forcing the heart to work harder. Veterinarians currently track the progression of this illness by listening to the heart, taking X-rays, and using ultrasound to measure the size of the heart chambers. They can tell when a dog is in an early stage where the heart is changing shape but the animal still feels fine, versus a later stage where the heart has become too strained and the dog is in heart failure. However, the tools used to spot the exact moment a dog is shifting from the early, manageable phase to the dangerous, failing phase are not perfect. Scientists have long suspected that the blood contains tiny molecular clues that reveal what is happening inside the heart before the ultrasound can see it, but finding those specific clues in dogs has been difficult.
A team of researchers at Kasetsart University in Thailand set out to find these hidden signals by looking directly at the proteins floating in the blood of dogs with this heart condition. They focused on two groups of dogs: twenty-six that were in the early stage of the disease, where the heart was enlarged but the dog was still active and symptom-free, and fifteen that had progressed to the stage of heart failure, where the heart was struggling to pump blood effectively. The researchers collected blood samples from all forty-one dogs and used a highly sensitive machine to sort through the thousands of different proteins in the plasma. This process allowed them to compare the molecular makeup of the blood between the two groups, searching for proteins that appeared in significantly different amounts as the disease worsened.
The study confirmed what veterinarians see on ultrasound scans: the dogs in the heart failure stage had significantly larger left ventricles, the main pumping chamber of the heart, and their hearts were filling with blood in a less efficient way. But the blood analysis revealed a deeper story. The researchers found that the blood of the dogs in the later stage was chemically distinct from the blood of the dogs in the earlier stage. By using statistical tools to filter out the noise, they identified eleven specific proteins that stood out as potential markers of the disease's progression. These proteins were not just random changes; they were involved in critical biological processes such as the body's immune response, how cells manage stress, and how the heart muscle breaks down and rebuilds itself.
Among the proteins identified, six appeared to have a direct link to the medications veterinarians commonly prescribe to treat heart failure, such as pimobendan and furosemide. This suggests that these proteins are part of the same biological pathways that the drugs are trying to influence. The other five proteins did not show a connection to these standard drugs, which makes them particularly interesting. The researchers propose that these five could serve as new, independent markers that tell the story of the disease itself, regardless of whether the dog is currently taking medication. This distinction is vital because it could help doctors see the true state of the disease without the signal being muddied by the treatment.
The study also looked at whether standard blood tests, which measure kidney and liver function, could tell the difference between the early and late stages. The results showed that these routine tests were nearly identical for both groups, meaning that a dog could be in advanced heart failure while still showing normal kidney and liver numbers. This finding reinforces the idea that the heart is failing locally without necessarily causing immediate, detectable damage to the rest of the body's organs. The researchers noted that the correlation between different heart measurements became much stronger in the dogs with heart failure, suggesting that as the disease progresses, the various parts of the heart and its blood flow become tightly linked in a coordinated breakdown.
While the findings are promising, the researchers are careful to note that this was a snapshot in time and the group of dogs with heart failure was relatively small. They have not yet confirmed these results with different testing methods, and they do not know exactly how these proteins behave over time as a dog moves from one stage to another. However, the work provides a clear list of candidate molecules that could one day be used to create a blood test for dogs. Such a test would allow veterinarians to detect the shift from a manageable heart condition to a critical failure much earlier than current methods allow, potentially leading to better timing for treatment and a longer, healthier life for dogs with this common heart disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.